Protein degradation by proteasomes plays an essential role in the proliferation of malignant cells. The proteasome inhibitor VELCADE (bortezomib, PS-341) is being used for the treatment of multiple myeloma and is in clinical trials for the treatment of other cancers. The proteasome has three types of active sites: chymotrypsin-like (Beta 5), trypsin-like (Beta 2), and caspase-like (Beta 1). Our long-term goal is to understand the precise roles of these active sites as targets of anti-neoplastic agents and to use this information to design new, more potent, less toxic drugs of this class. Bortezomib was developed as an inhibitor of the Beta 5 site, which has long been considered the only suitable target for inhibition. However, bortezomib also inhibits the (Beta 1 site, and we have recently obtained data showing that inhibition of the Beta 1 site is needed to achieve maximal cytotoxicity. Based on these data and on critical review of the literature, we hypothesize that (a) all three active sites are drug molecular targets, (b) inhibition of at least two sites is required to achieve optimal cytotoxicity, (c) the therapeutic windows of proteasome inhibitors depend on which active sites they target, and (d) the exact pathways by which proteasome inhibitors induce apoptosis in malignant cells depend on which active sites they target. We will test this hypothesis in multiple myeloma and breast cancer cells using unique, cell-permeable, specific inhibitors of proteasome catalytic sites that we have developed and are developing.
The specific aims of this proposal are as follows: (1) To determine the growth inhibitory and cytotoxic effects of specific inhibitors of (Beta 5, Beta1, and Beta 2 catalytic sites, alone and in combination with each other, on cells derived from multiple myeloma and breast cancers, on immortalized and transformed human mammary epithelial cells, and on human peripheral blood lymphocytes;(2) To determine whether the mechanisms by which proteasome inhibitors kill multiple myeloma cells depend on the catalytic sites being targeted by these agents;The results of these studies will define what active-site pharmacological specificities proteasome inhibitors must have to achieve optimal anti-neoplastic activity and therapeutic windows. Taken together, these studies will provide a strong rationale for development of novel inhibitors with desired molecular pharmacological properties. Such compounds have potentially broad applicability for cancer therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA124634-03S1
Application #
7909242
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Arya, Suresh
Project Start
2009-08-01
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2011-07-31
Support Year
3
Fiscal Year
2009
Total Cost
$270,180
Indirect Cost
Name
Dartmouth College
Department
Pharmacology
Type
Schools of Medicine
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Kisselev, Alexei F; Groettrup, Marcus (2014) Subunit specific inhibitors of proteasomes and their potential for immunomodulation. Curr Opin Chem Biol 23:16-22
Wilkins, Owen M; Downey, Sondra L; Weyburne, Emily S et al. (2014) Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity. Anal Biochem 451:1-3
Shabaneh, Tamer B; Downey, Sondra L; Goddard, Ayrton L et al. (2013) Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS One 8:e56132
Geurink, Paul P; van der Linden, Wouter A; Mirabella, Anne C et al. (2013) Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. J Med Chem 56:1262-75
van der Linden, Wouter A; Willems, Lianne I; Shabaneh, Tamer B et al. (2012) Discovery of a potent and highly ?1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones. Org Biomol Chem 10:181-94
Kisselev, Alexei F; van der Linden, Wouter A; Overkleeft, Herman S (2012) Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 19:99-115
Mirabella, Anne C; Pletnev, Alexandre A; Downey, Sondra L et al. (2011) Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem Biol 18:608-18
Reis, Julia; Guan, Xiu Qin; Kisselev, Alexei F et al. (2011) LPS-induced formation of immunoproteasomes: TNF-? and nitric oxide production are regulated by altered composition of proteasome-active sites. Cell Biochem Biophys 60:77-88
Florea, Bogdan I; Verdoes, Martijn; Li, Nan et al. (2010) Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t. Chem Biol 17:795-801
Verdoes, Martijn; Willems, Lianne I; van der Linden, Wouter A et al. (2010) A panel of subunit-selective activity-based proteasome probes. Org Biomol Chem 8:2719-27

Showing the most recent 10 out of 13 publications